Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (RCKT)
NASDAQ:RCKT
RCKT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.06 - $27.71
Previous CloseN/A
Volume339.48K
Average Volume (3M)1.45M
Market Cap
$898.89M
Enterprise Value$1.53B
Total Cash (Recent Filing)$111.36M
Total Debt (Recent Filing)$41.45M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
May 07, 2025EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.73
Shares Outstanding106,629,700
10 Day Avg. Volume1,648,841
30 Day Avg. Volume1,446,973
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-215.43
Enterprise Value/Ebitda-6.19
Forecast
1Y Price Target
$42.00Price Target Upside381.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe completed enrollment of the low dose cohort in RP-A601's Ph1 trial for PKP2-ACM is a significant development, with initial data expected soon.
Financial PositionRCKT ended with $372.3M in cash, which is expected to be sufficient into 3Q26.
Market OpportunityRP-A601 for Plakophilin-2 Related Arrhythmogenic Cardiomyopathy could confer a larger commercial opportunity, despite not being clinically derisked yet.
Therapeutic PotentialRCKT's therapies likely offer a life-long effect as they target the heart, unlike most liver-targeted gene therapies with limited durability.
Bears Say
Regulatory ChallengesCRL for Kresladi in leukocyte adhesion deficiency-1 (LAD-1) indicates challenges with FDA review.
Stock ValuationThe price target was decreased to $36 from $39 following the 4Q24 earnings and public offering.
---
Ownership Overview
34.67% Insiders
22.53% Mutual Funds
0.51% Other Institutional Investors
30.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCKT FAQ
What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was $8.06 and its highest was $27.71 in the past 12 months.
What is Rocket Pharmaceuticals’s market cap?
Rocket Pharmaceuticals’s market cap is $898.89M.
When is Rocket Pharmaceuticals’s upcoming earnings report date?
Rocket Pharmaceuticals’s upcoming earnings report date is May 07, 2025 which is in 43 days.
How were Rocket Pharmaceuticals’s earnings last quarter?
Rocket Pharmaceuticals released its earnings results on Feb 27, 2025. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.718 by $0.098.
Is Rocket Pharmaceuticals overvalued?
According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued.
Does Rocket Pharmaceuticals pay dividends?
Rocket Pharmaceuticals does not currently pay dividends.
What is Rocket Pharmaceuticals’s EPS estimate?
Rocket Pharmaceuticals’s EPS estimate is -0.59.
How many shares outstanding does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals has 106,629,700 shares outstanding.
What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
Rocket Pharmaceuticals reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.718. Following the earnings report the stock price went up 0.532%.
Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
Currently, no hedge funds are holding shares in RCKT
---
Rocket Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.00 (381.10% Upside)
$42.00 (381.10% Upside)
Blogger Sentiment
Bullish
RCKT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 700.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $533.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.91%
12-Months-Change
Fundamentals
Return on Equity
-54.14%
Trailing 12-Months
Asset Growth
-6.82%
Trailing 12-Months
Company Description
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. (RCKT) is a clinical-stage biotechnology company focused on developing first-in-class gene therapies for rare and devastating diseases. The company operates in the pharmaceutical sector, primarily targeting inherited genetic disorders with high unmet medical needs. Rocket Pharmaceuticals leverages its proprietary lentiviral vector platform to develop gene therapies aimed at providing long-lasting and potentially curative treatments for patients.
---
RCKT Stock 12 Month Forecast
Average Price Target
$42.00
▲(381.10% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering RCKT
1 Year
1 Year Success Rate
14/23 ratings generated profit
1 Year Average Return
+26.36%
reiterated a buy rating 26 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 60.87% of your transactions generating a profit, with an average return of +26.36% per trade.
---